{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:06:30Z","timestamp":1794647190040,"version":"4.9.1"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["No. LBY21H270001"],"award-info":[{"award-number":["No. LBY21H270001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>We performed a single-arm meta-analysis to evaluate the efficacy and safety of JAK inhibitors in the treatment of dermatomyositis (DM)\/ polymyositis (PM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Relevant studies from four databases were systematically searched until April 25, 2023. The primary endpoint was Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and other outcomes were Manual Muscle Testing (MMT) and Creatine Kinase (CK). According to the type of JAK and medication regimen, we conducted subgroup analyses. The registration number in PROSPERO was CRD42023416493.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>According to the selection criteria, we identified 7 publications with a total of 91 patients. Regarding skin lesions, the CDASI decreased by 17.67 (95% CI: -20.94 ~ -14.41). The CK increased by 8.64 U (95% CI: -28.25 ~ 45.53). About muscle lesions, MMT increased by 10.31 (95% CI: -2.83 ~ 23.46). Subgroup analysis revealed that different types of JAK inhibitors had various degrees of reduction. CDASI in patients treated with RUX had the lowest one [-20.00 (95% CI: -34.9 ~ -5.1)], followed by TOF [-18.29 (95% CI: -21.8 ~ -14.78)] and BAR [-11.2 (95% CI: -21.51 ~ -0.89)]. Additionally, the mean reduction in CDASI in patients treated with TOF alone was 16.16 (95% CI: -21.21 ~ -11.11), in combination with other immunosuppressants was 18.59 (95% CI: -22.74 ~ -14.45). For safety evaluation, one patient developed Orolabial HSV, and two patients developed thromboembolism events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>In summary, this meta-analysis demonstrated that JAK inhibitors can potentially treat DM\/PM without severe adverse reactions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?ID=CRD42023416493<\/jats:uri>, identifier CRD42023416493.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1382728","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T05:11:40Z","timestamp":1710997900000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Therapeutic efficacy and safety of JAK inhibitors in treating polymyositis\/dermatomyositis: a single-arm systemic meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Chenhang","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08786-6","article-title":"JAK inhibitors: prospects in connective tissue diseases","volume":"59","author":"You","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e14939","DOI":"10.1111\/dth.14939","article-title":"JAK-inhibitors for dermatomyositis: A concise literature review","volume":"34","author":"Paudyal","year":"2021","journal-title":"Dermatol Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.311","article-title":"High-intensity induction therapy combining tofacitinib, rituximab, and plasmapheresis in rapidly progressive interstitial lung disease associated with anti-mda5 antibody positive dermatomyositis","volume":"81","author":"Shirai","year":"2022","journal-title":"Ann Rheumat Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab116","article-title":"JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study","volume":"60","author":"Le Voyer","year":"2021","journal-title":"Rheumatology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220367","article-title":"A retrospective analysis of outcome in melanoma differentiation-associated gene 5-related interstitial lung disease treated with tofacitinib or tacrolimus","volume":"49","author":"Fan","year":"2022","journal-title":"J Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.10.055","article-title":"JAK inhibitors for the treatment of adult dermatomyositis: A pilot study","volume":"88","author":"Landon-Cardinal","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/art.41108","article-title":"JAK inhibitors: A promising molecular-targeted therapy in dermatomyositis","volume":"17","author":"Landon-Cardinal","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/art.41944","article-title":"Long-term extension study of tofacitinib in refractory dermatomyositis","volume":"74","author":"Paik","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.07.003","article-title":"Tofacitinib as treatment for refractory dermatomyositis: A retrospective study from 2 academic medical centers","volume":"86","author":"Min","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/24725625.2020.1816674","article-title":"Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies","volume":"5","author":"Ohmura","year":"2021","journal-title":"Mod Rheumatol Case Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1382728\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T05:11:44Z","timestamp":1710997904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1382728\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":12,"alternative-id":["10.3389\/fimmu.2024.1382728"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1382728","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2024.1382728.s001","asserted-by":"subject"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,21]]},"article-number":"1382728"}}